Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GlucoTrack, Inc. - Common Stock (NQ:GCTK)

0.4300 -0.0470 (-9.85%)
Streaming Delayed Price Updated: 2:02 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GlucoTrack, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
CORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
From Lōkahi Therapeutics Inc.
Via Business Wire
News headline image
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
From Lōkahi Therapeutics Inc.
Via Business Wire
News headline image
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
From Glucotrack, Inc.; Lōkahi Therapeutics
Via GlobeNewswire
News headline image
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and... 
From Glucotrack, Inc.; Lōkahi Therapeutics
Via GlobeNewswire
News headline image
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and... 
From Glucotrack, Inc.; Lōkahi Therapeutics
Via GlobeNewswire
News headline image
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE Submission 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and... 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack, Inc. Encourages Shareholders to Vote
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
Renowned pain management and medical technology leader to accelerate Glucotrack’s strategy for integrated glucose monitoring applications, building on Company’s 2024 expansion into epidural monitoring 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack, Inc. Reminds Shareholders to Vote
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Q3 Virtual Investor Summit: On-Demand Presentations Now Available
Via ACCESS Newswire
News headline image
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
Via ACCESS Newswire
News headline image
Glucotrack to Participate in the Q3 Virtual Investor Summit
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
Experienced cardiac electrophysiologist joins Glucotrack’s growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot study 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces Repurchase of Series A Warrants
Warrant buyback extinguishes warrant liability accounting and share dilution overhang 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
Comprehensive analysis confirms safety and strong accuracy of Glucotrack's innovative blood-based continuous glucose monitoring technology, with MARD of 7.7% 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management
Via TheNewswire.com
News headline image
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives
Via TheNewswire.com
News headline image
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology 
From Glucotrack, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.